RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines

Chemico-Biological Interactions

Volumn 203, Issue 2, 2013, Pages 467-479

  Naidu, V G M ^a   Dinesh Babu, Kuppan Rajendran ^a   Thwin, Maung Maung ^a   Satish, R L ^a   Kumar, Prem V ^a   Gopalakrishnakone, P ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Arthritis; NF B; Osteoprotegrin; Peptidomimetics; RANK; RANKL

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CELECOXIB; ER 7 PEPTIDE; ER 9 PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LR 10 PEPTIDE; OPG 3 PEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; YR 11 CYC PEPTIDE; YR 11 PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BONE ATROPHY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; RHEUMATOID ARTHRITIS; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CELL LINE; CELL PROLIFERATION; CYTOKINES; DOWN-REGULATION; FIBROBLASTS; MALE; MICE; MOLECULAR TARGETED THERAPY; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; OSTEOCLASTS; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROTEIN BINDING; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; SYNOVIAL MEMBRANE;

RATTUS;

EID: 84875986560     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2012.12.016     Document Type: Article

References (25)

1. M.C. Bezerra, J.F. Carvalho, A.S. Prokopowitsch, and R.M. Pereira RANK, RANKL and osteoprotegerin in arthritic bone loss Braz J Med Biol Res 38 2005 161 170
2. Q. Rehman, and N.E. Lane Bone loss therapeutic approaches for preventing bone loss in inflammatory arthritis Arthritis Res 3 2001 221 227
3. B. Bolona, G. Campagnuolob, and U. Feige Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis CMLS Cell Mol Life Sci 59 2002 1569 1576
4. X. Cheng Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo J Biol Chem 279 2003 8269 8277
5. D.J. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux, R. Murali, and P.I. Croucher An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma Cancer Res 67 2007 202 208
6. J.M. Mason Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention Future Med. Chem. 2 2010 1813 1822
7. M. Verdrengh, M. Bokarewa, C. Ohlsson, M. Stolina, and A. Tarkowski RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis Bone 46 2010 752 758
8. K. Wakamatsu, T. Nanki, N. Miyasaka, K. Umezawa, and T. Kubota Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells Arthritis Res Ther 7 2005 R1348 R1359
9. H. Ichikawa 1′-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-κB activation Mol Cancer Res 4 2006 275 281
10. K. Igarashi, J.T. Woo, and P.H. Stern Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro Biochem Pharmacol 63 2002 523 532
11. W.V. Eden, J.P.A.W. Hilbers, and M.H.M. Wauben Adjuvant arthritis in the rat Curr Protoc Immunol 15 2001 15.14.11 15.14.18
12. H.S. Kim, A.R. Kim, H.J. Park, D.K. Park, D.K. Kim, N.Y. Ko, B. Kim, D.K. Choi, H.S. Won, W.S. Shin, Y.M. Kim, and W.S. Choi Morus bombycis Koidzumi extract suppresses collagen-induced arthritis by inhibiting the activation of nuclear factor-κB and activator protein-1 in mice J Ethnopharmacol 136 2011 392 398
13. S. Reuter, S. Prasad, K. Phromnoi, R. Kannappan, V.R. Yadav, and B.B. Aggarwal Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway Mol Cancer Res 8 2010 1425 1436
14. N.T. Moldogazieva, A.A. Terentiev, A.N. Kazimirsky, M.Y. Antonov, and K.V. Shaitan Conformational dynamics of human α-fetoprotein-derived heptapeptide LDSYQCT analogs Biochemistry (Moscow) 72 2007 529 539
15. B.W. Chen, J.W. Yewdell, R.L. Levine, and J.R. Bennink Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants J Exp Med 189 1999 1757 1764
16. H.J. Choi, Y.R. Park, M. Nepal, B.-Y. Choi, N.-P. Cho, S.H. Choi, S.R. Heo, H.S. Kim, M.-S. Yang, and Y. Soh Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways Eur J Pharmacol 636 2010 28 35
17. Y. Lee, J. Lee, E. Noh, E. Kim, M. Song, W. Jung, S. Park, J. Kim, J. Park, and K. Kwon Guggulsterone blocks IL-1β-mediated inflammatory responses by suppressing NF-κB activation in fibroblast-like synoviocytes Life Sci 82 2008 1203 1209
18. E. Jimi, K. Aoki, H. Saito, F. D'Acquisto, M.J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, H. Fukushima, K. Okabe, K. Ohya, and S. Ghosh Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo Nat Med 10 2004 617 624
19. M. Urushibara, H. Takayanagi, T. Koga, S. Kim, M. Isobe, Y. Morishita, T. Nakagawa, M. Leffler, T. Kodama, H. Kurosawa, and T. Taniguchi The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kB ligand-stimulated induction of nuclear factor of activated T cells c1 Arthritis Rheum 50 2004 794 804
20. S. Kotake, T. Yago, M. Kawamoto, and Y. Nanke Effects of NSAIDs on differentiation and function of human and murine osteoclasts-crucial 'human osteoclastology' Pharmaceuticals 3 2010 1394 1410
21. S. Vitovski, J.S. Phillips, J. Sayers, and P.I. Croucher Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways J Biol Chem 282 2007 31601 31609
22. J.H. Lee, H.N. Kim, D. Yang, K. Jung, H.M. Kim, H.H. Kim, H. Ha, and Z.H. Lee Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling J Biol Chem 284 2009 13725 13734
23. M. Tunyogi-Csapo, K. Kis-Toth, M. Radacs, B. Farkas, J.J. Jacobs, A. Finnegan, K. Mikecz, and T.T. Glant Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption Arthritis Rheum 58 2008 2397 2408
24. S. Hermeling, D.J. Crommelin, H. Schellekens, and W. Jiskoot Structure immunogenicity relationships of therapeutic proteins Pharm Res 21 2004 897 903
25. H. Schellekens Immunogenicity of therapeutic proteins: clinical implications and future prospects Clin Ther 24 2002 1720 1740